Oncodesign Precision Medicine - OPM
Jan Hoflack has an extensive work experience in the pharmaceutical and biotech industries. Jan currently holds the position of Chief Scientific Officer at Oncodesign Precision Medicine - OPM since 2022. Prior to this, they worked at Oncodesign as CSO and VP Discovery, leading new business units for integrated discovery programs as a service to partners. Jan also had leadership roles at Johnson & Johnson, AstraZeneca, and Novartis, where they were responsible for medicinal chemistry, enabling sciences and technologies, and structural biology and molecular modelling. Jan started their career as a Research Scientist at Marion Merrell Dow, where they worked on a CNS project and led a team of researchers.
Jan Hoflack completed their high school education from Sint-Lodewijkscollege Bruges between 1972 and 1978, majoring in Latin-Mathematics. Jan then pursued a PhD in Chemistry, specializing in Organic Synthesis, from State University Ghent, which they completed between 1980 and 1987.
This person is not in any teams
This person is not in any offices
Oncodesign Precision Medicine - OPM
OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com